What We're Reading: Page
Industry reads hand-picked by our editors
Jul 27, 2023
Jul 26, 2023
-
The Wall Street Journal
A Surprising Beneficiary of New Alzheimer’s Drugs: GE HealthCare
-
Evaluate Vantage
GSK admits anaemia defeat
-
Financial Times
UK billionaire Joe Lewis surrenders to US authorities on insider trading charges
-
Stat News
Asian American doctors, overrepresented in medicine, are largely left out of leadership
Jul 25, 2023
Jul 24, 2023
-
The New York Times
How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy
-
The Boston Globe
Rise in cancer among younger people worries and puzzles doctors
-
Boston Business Journal
Serial biotech entrepreneur Greg Verdine joins Andreessen Horowitz
Jul 21, 2023
Jul 20, 2023
-
The Pharma Letter
Sosei Heptares acquires Idorsia’s pharma business in Japan and beyond
-
AP News
Tornado damages Pfizer plant in North Carolina as scorching heat and floods sock other parts of US
-
BioCentury
U.K. proposes model to value any antimicrobial as a subscription
-
Axios
Why mainstreaming psychedelics isn’t generating a fuss
Jul 19, 2023
-
Bloomberg
Eyedrop Recall 2023 and Infections Were Result of Lack of FDA Regulation
-
The Wall Street Journal
Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In.
-
Nature
Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed?
-
Harper’s Magazine
Love in the Time of Sickle Cell Disease
Previous
